{"id":"nct:NCT04807400","kind":"trial","title":"Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2021,"published":"2021-03-19","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04807400","source_url":"https://clinicaltrials.gov/study/NCT04807400","archive_url":"https://space-kitty.com/papers/nct:NCT04807400","updated":"2024-10-09","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of \"bad\" cholesterol (LDL-cholesterol) in the blood. Inclisiran works in a way that makes the liver produce less of a substance called 'PCSK9'. PCSK9 reduces the ability of the liver to remove LDL-cholesterol from the blood. By lowering the production of PCSK9, Inclisiran leads to more LDL-cholesterol being removed by the liver from the blood, thereby reducing LDL-cholesterol overall.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Atherosclerotic Cardiovascular Disease","Atherosclerotic Cardiovascular Disease Risk Equivelents","Elevated Low Density Lipoprotein Cholesterol"],"details":{"acronym":"SPIRIT","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":892,"sponsor":"Novartis Pharmaceuticals","conditions":["Atherosclerotic Cardiovascular Disease","Atherosclerotic Cardiovascular Disease Risk Equivelents","Elevated Low Density Lipoprotein Cholesterol"],"interventions":["DRUG: Inclisiran","BEHAVIORAL: Behavioural Support","DRUG: Background lipid lowering therapy"],"start_date":"2021-07-07","start_date_type":"ACTUAL","primary_completion_date":"2023-01-13","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}